Angel Adegbesan,

Angel Adegbesan is a financial journalist at Bloomberg News. He covers the pharmaceutical and biotech industries with a focus on market-moving events that impact investors. Prior to joining Bloomberg, Angel worked as an equity research analyst for several years, providing insights on companies in the healthcare sector. His articles often discuss stock performance and corporate developments within the industry.

Biography:  https://www.bloomberg.com/authors/AVmRj2dywwc/angel-adegbesan

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

Novavax and Sanofi's $1.2 Billion Deal: Developing a COVID-19 and Flu Vaccine Combination

Novavax and Sanofi's $1.2 Billion Deal: Developing a COVID-19 and Flu Vaccine Combination

Broke On: Friday, 10 May 2024 Novavax and Sanofi announce a $1.2 billion deal to co-develop COVID-19 and flu vaccines, with an upfront payment of $500 million from Sanofi to Novavax and potential payments of up to $700 million based on milestones.